Most Recent
‘Contingency on contingency’: Judge won’t halt IP dispute over Abilify generic
The Commonwealth has lost its bid to pause a long-running dispute over a generic form of brand drug Abilify while the High Court hears a different generic drug battle.
Judge approves settlement in Retail Food Group class action
A judge has signed off on a class action settlement that will see Retail Food Group pay nothing to the current and former franchisees of its Michel’s Patisserie chain.
JWS nabs Corrs Chambers pair for industrial relations team
Johnson Winter Slattery has bolstered the ranks of its industrial relations and employment team, luring a new partner and special counsel away from Corrs Chambers Westgarth. 
Cipla attacks patent extension for Novo Nordisk weight loss drug
Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.
Government wants to stay 12-year-old dispute over Abilify generic
The Commonwealth has argued that a long-running dispute involving drug makers Otsuka, Bristol-Myers Squibb and Generic Health should be put on ice until the High Court rules in a separate matter.
AstraZeneca sues to put the brakes on Brilinta generic
AstraZeneca has brought court proceedings to block Australian drug maker Pharmacor from making a generic version of its heart attack drug Brilinta. 
IP case over basmati rice to venture into ‘darker corners’ of trade mark law
The scope of protection for geographical indications will be at issue in India's appeal of a decision that barred it from registering a trade mark for basmati rice.
INPEX can cross-examine AkzoNobel’s lawyers over ‘inadequate’ discovery
INPEX has won a bid to cross-examine AkzoNobel's solicitors about discovery at the end of an 11-week trial over allegedly defective paint used on the $45 billion Ichthys natural gas project. 
New battle in Lexapro patent war between Lundbeck, Sandoz
Novartis unit Sandoz is appealing a tribunal decision in favour of pharmaceutical company Lundbeck over a licence to sell a generic version of leading antidepressant Lexapro.